ГОСТ Р 57130—2016
Библиография
1 Ashby J. Paton D. The Influence of chemical structure on the extent and sites of carcinogenesis for 522 rodent
carcinogens and 55 different human carcinogen exposures.Mutat Res 1994.286: 3—74.
2 CorviR. AlbertmiS, Hartung T, HoffmannS. MaunciD, PfuhlerS etal. ECVAM Retrospective Validation of the
in vilro micronucleus test <MNT). Mutagenesis 2008; 23:271—283.
3 Gatehouse D. Haworth S. Cebula T. Gocke E. KierL. Matsushima T etal. Report from the working group on bacterial
mutation assays: internationalworkshopon standardisation ofgenotoxicity test procedures. Mutat Res 1994; 312:217—33.
4 Goodman & Gilman. The pharmacologicalbasis of therapeutics. Hardman JG. Llmbird LE.Gilman AG. editors. 10th
ed. New York: McGraw-Hill Professional 2001.
5 Greenwood SK. Hill RB. Sun JT.Armstrong MJ. Johnson ТЕ. Gara JP etal. Population Doubling: A simple and more
accurate estimation of cell growth suppression In the in vitro assay for chromosomal aberrations that reduces irrelevant
positive results. Environ Mol Mutagen 2004;43: 36—44.
6 Hamada S.. Sutou S. Morita T, Wakata A. Asanami S. Hosoya S et al. Evaluation of the rodent micronucleus assay
by a 28-day treatment protocol:summaryofthe
1
3th collaborative study by the collaborative study group forthe micronucteus
test (CSGMT)/Envlronmental Mutagen Society ofJapan (JEMS) — Mammalian Mutagenicity Study Group (MMS). Environ
Mol Mutagen 2001 ;37:93—110.
7 Hartmann A. Agurell E. Beevers C. Brendler-Schwaab S. Burtinson B. Clay P et al. Recommendations for
conducting the in v/vo alkaline Comet assay. Mutagenesis 2003;18:45-51.
8 Hayashi M. MacGregor JT. Gatehouse DG. Adler I. Blakey DH. Dertinger SD et al. In vivo rodent erythrocyte
micronucleus assay. II. Some aspects of protocol design including repeated treatments, integration with toxicity testing, and
automated scoring. Environ Mol Mutagen 2000;35: 234—52.
9 Hayashi M. MacGregor JT. Gatehouse DG, Blakey DH. Dertinger SD. Abramsson-Zetterberg L et al. In vivo
erythrocyte micronucleus assay. III. Validation and regulatory acceptance of automated scoring and the use ofrat peripheral
blood reticulocytes, with discussion of non-hematopoletic target cells and a single dose-levellimit test. Mutat Res 2007;627:
10— 30.
10 Heddle JA. Dean S. Nohmi T. Boerrigter M, Casciano D. Douglas GR et al. In vivo transgenic mutation assays.
Environ Mol Mutagen 2000; 35:253.
11 Hotchkiss CE. Bishop ME. Dertinger SD. Slikker W. Moore MM. MacGregor JT. Flow cytometric analysis of
micronuclei in peripheral blood reticulocytes IV: an index of chromosomal damage in the rhesus monkey (macaca mulatta).
Toxicol Sci 2008 ;102: 352—8
12 Kasper P. Uno Y. Mauthe R. Asano N. Douglas G. Matthews E et al. Follow-up testing of rodent carcinogens not
positive In the standard genotoxlclty testing battery: IWGT workgroup report. Mutat Res 2007:627; 106—116.
13 Kenelly JC. Waters R. Ashby J. Lefevre PA. Burlmson B. Benford DJ et al. in vivo rat liver UDS assay. In:
Supplementary Mutagenicity Tests. UKEMS Recommended Procedures. Kirkland DJ. Fox M. editors. Cambridge University
Press 1993; 52—77.
14 Kirkland DJ.Pfuhler S.Tweats D. AardemaM. CorviR. DarroudiF etal. How to reduce false positive results when
undertaking In vitro genotoxlclty testing and thus avoid unnecessary follow-up animal tests: report of the ECVAM workshop.
Mutat Res 2007;628: 31—55.
15 Kirsch-Volders M. Sofunl T. Aardema M. Albertlnl S. Eastmond D. Fenech M et al. Report from the in vitro
micronucleus assay working group. Mutat Res 2003.540:153—63.
16 Kissllng GE. Dertinger SD. Hayashi M. MacGregor JT. Sensitivity of the erythrocyte micronucleus assay;
dependence on number of cells scored and inter-animal variability. Mutat Res 2007;634:235—40.
17 Ku WW. Bigger A. Brambllta G. Glatt H. Gocke E. Guzzie PJ et al. Strategy for genotoxlcity testing-metabolic
considerations. Mutat Res 2007:627: 59—77.
18 MacGregor JT. Bishop ME. McNamee JP. Hayashi M. Asano N. Wakata A et al. Flow Cytometric analysis of
micronuclei In peripheral blood reticulocytes: II. An efficient method of monitoring chromosomal damage in the rat. Toxicol Sci
2006;94: 92— 107.
19 Moore MM. Honma M. Clements J, Harnngton-Brock K. Awogl T. Bolcsfoldi G et at. Mouse lymphoma thymidine
kinase locus gene mutation assay: follow-up International workshop on genotoxicity test procedures — New Orleans.
Louisiana. April 2000. Environ Mol Mutagen 2002;40:292-9.
20 Moore MM. Honma M. Clements J. Bolcsfoldi G. Burlmson B.Cifone M etal. Mouse lymphoma thymidine kinase
gene mutation assay, follow-up meeting of the international workshop on genotoxlclty testing — Aberdeen. Scotland.
2003 — Assay acceptance criteria, positive controls, and data evaluation. Environ Mol Mutagen 2006:47:1—5.
21 Muller L. Kasper P. Human biological relevance and the use of threshold arguments In regulatory genotoxlclty
assessment: experience with pharmaceuticals. Mutat Res 2000;464:9—34.
22 OECD Guidelines for Genetic Toxicology 1997.
23 Scott D, Galloway SM. Marshall RR. Ishidate M Jr. Bruslck D. Ashby J et al. Genotoxicity under extreme culture
conditions. A report from ICPEMC task group 9. Mutat Res 1991.257:147—204.
19